Guillermo Torre, MD, PhD

Professor of Cardiology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Torre-Amione received his first academic appointment in 1995 as a Clinical Instructor at the Baylor College of Medicine in Houston, Texas. He became an Assistant Professor there one year later, the same year he became the Medical Director for the Cardiac Transplant Service at Houston Methodist DeBakey Heart and Vascular Center. Dr.Torre-Amione joined the Houston Methodist Specialty Physician Group and Weill Medical College in 2005.

Description of Research

Dr. Torre-Amione is the director of the Heart Failure Research Laboratory at Houston Methodist, and conducts research examining the mechanisms of immune activation and inflammation as it relates to myocardial dysfunction in the areas of heart failure and cardiac transplantation. The doctor and his colleagues have conducted numerous studies that suggest novel immune modulatory therapies for the treatment of heart failure and transplant patients. Dr. Torre-Amione led the first two FDA-approved trials of Celacade with impressive results, and a Phase III trial is underway. Other studies underway in the Heart Failure Research Laboratory are investigating additional immune response pathways that contribute to the progression of heart failure, including the role of heat shock proteins and cardiac mast cells.

Areas Of Expertise

Heart failure Inflammation Cardiac transplant Immune activation Heat shock proteins Cardiac mast cells
Education & Training

Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
Postdoctoral Fellowship, Baylor College of Medicine
MD, Facultad De Medicina - Instituto Tech.
PhD, University of Chicago

Management of Myocarditis-Related Cardiomyopathy in Adults
Tschöpe, C, Cooper, LT, Torre, G & Van Linthout, S 2019, Circulation Research, vol. 124, no. 11, pp. 1568-1583.

Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: Study protocol
Sánchez-Trujillo, L, Jerjes-Sanchez, C, Rodriguez, D, Panneflek, J, Ortiz-Ledesma, C, Garcia-Rivas, G & Torre, G 2019, BMJ open, vol. 9, no. 3, 022826.

Mitochondrial Hyperacetylation in the Failing Hearts of Obese Patients Mediated Partly by a Reduction in SIRT3: The Involvement of the Mitochondrial Permeability Transition Pore
Castillo, EC, Morales, JA, Chapoy-Villanueva, H, Silva-Platas, C, Treviño-Saldaña, N, Guerrero-Beltrán, CE, Bernal-Ramírez, J, Torres-Quintanilla, A, García, N, Youker, K, Youker, KA & Torre, G 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, vol. 53, no. 3, pp. 465-479.

Temporal frame of immune cell infiltration during heart failure establishment: Lessons from animal models
Brenes-Castro, D, Castillo, EC, Vázquez-Garza, E, Torre, G & García-Rivas, G 2018, International journal of molecular sciences, vol. 19, no. 12, 3719.

B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study
Rodriguez, D, Garcia-Rivas, G, Laresgoiti-Servitje, E, Yañez, J, Torre, G & Jerjes-Sanchez, C 2018, BMJ open, vol. 8, no. 10, pp. e022562.

The use of cardiac CT as a roadmap for resolving coronary stent dislodgement
Torre, G, de la Pena-Almaguer, E, Quintanilla, J, Valdes, F, Jimenez, V, Rodriguez, D, Trevino, A, Perez, L & Jerjes-Sanchez, C 2018, Archivos de cardiologia de Mexico, vol. 88, no. 4, pp. 318-319.

IABP as a Bridge to Transplantation: Can we Identify Who May Benefit From a LVAD?
Guha, A, Ali, A, Nguyen, DT, Bruckner, B, Trachtenberg, B, Graviss, EA, Bhimaraj, A, Park, MH, Hussain, I, Suarez, EE, Torre-Amione, G & Estep, J 2018, Journal of Heart and Lung Transplantation, vol. 37, no. 4, pp. S267.

Melding a high-risk patient for continuous flow left ventricular assist device into a low-risk patient
Amione-Guerra, J, Cruz-Solbes, AS, Bonilla, HG, Estep, JD, Guha, A, Bhimaraj, A, Suarez, EE, Bruckner, BA, Torre-Amione, G, Park, MH & Trachtenberg, BH 2017, ASAIO Journal, vol. 63, no. 6, pp. 704-712.

Risk Stratification of Patients With Current Generation Continuous-Flow Left Ventricular Assist Devices Being Bridged to Heart Transplantation
Guha, A, Nguyen, D, Cruz-Solbes, AS, Amione-Guerra, J, Schutt, RC, Bhimaraj, A, Trachtenberg, BH, Park, MH, Graviss, EA, Gaber, O, Suarez, E, Montane, E, Torre-Amione, G & Estep, JD 2017, ASAIO Journal, pp. 196-202.

Prevalence of in-hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure
Alvarez, PA, Putney, D, Ogunti, R, Puppala, M, Ganduglia, C, Torre-Amione, G, Schutt, R, Wong, STC & Estep, JD 2017, Cardiovascular Therapeutics, vol. 35, no. 3.

Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS)
for the VERITAS Investigators 2017, European Journal of Heart Failure, vol. 19, no. 6, pp. 739-747.

Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension
Segura-Ibarra, V, Amione-Guerra, J, Cruz-Solbes, AS, Cara, FE, Iruegas-Nunez, DA, Wu, S, Youker, KA, Bhimaraj, A, Torre-Amione, G, Ferrari, M, Karmouty-Quintana, H, Guha, A & Blanco, E 2017, International Journal of Pharmaceutics, vol. 524, no. 1-2, pp. 257-267.

Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials
ENABLE Investigators and Committees & ENABLE Investigators and Committees 2017, JACC: Heart Failure, vol. 5, no. 5, pp. 317-326.

Cardiovascular efficacy and safety of bococizumab in high-risk patients
SPIRE Cardiovascular Outcome Investigators 2017, New England Journal of Medicine, vol. 376, no. 16, pp. 1527-1539.

Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against ß1-Adrenergic Receptors
Nagatomo, Y, McNamara, DM, Alexis, JD, Cooper, LT, Dec, GW, Pauly, DF, Sheppard, R, Starling, RC, Tang, WHW, McNamara, DM, Janosko, K, McTiernan, C, London, B, Hanley-Yanez, K, Gorcsan, J, Tanaka, H, Suffoletto, M, Starling, RC, Oblak, C, Cooper, LT, McNallan, A, Koenig, LA, Mather, P, Pierson, N, Rubin, S, Bell, Y, Ervin, A, Boehmer, J, Frey, P, Alexis, J, Schrack, J, LaDuke, P, Torre, G, Arredondo, J, Pauly, DF, Smith, PC, Sheppard, R, Fuoco, S, Wittstein, IS, Breton, E, Thohan, V, Wesley, D, Dec, GW, Cocca-Spofford, D, Markham, DW, Fernandez, L, Debes, C, Zucker, MJ, Adams, L, Liu, P, Renton, J, Narula, J, Allen, B & Westberg, E 2017, Journal of the American College of Cardiology, vol. 69, no. 8, pp. 968-977.

The Obesity Paradox in End Stage Heart Failure: Does LVAD Resolve the Paradox?
Cruz-Solbes, AS, Nguyen, DT, Trachtenberg, B, Bhimaraj, A, Torre-Amione, G, Graviss, EA, Estep, JD & Guha, A 2017, Journal of Cardiac Failure, vol. 23, no. 8, pp. S17.

Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence
Sánchez-Trujillo, L, Vázquez-Garza, E, Castillo, EC, García-Rivas, G & Torre, G 2017, Archives of Medical Research, vol. 48, no. 1, pp. 1-11.

Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload
Oropeza-Almazán, Y, Vázquez-Garza, E, Chapoy-Villanueva, H, Torre, G & García-Rivas, G 2017, Oxidative Medicine and Cellular Longevity, vol. 2017, 5750897.

Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca2+ handling in adult rat cardiomyocytes
Guerrero-Beltrán, CE, Bernal-Ramírez, J, Lozano, O, Oropeza-Almazán, Y, Castillo, EC, Garza, JR, García, N, Vela, J, García-García, A, Ortega, E, Torre, G, Ornelas-Soto, N & García-Rivas, G 2017, American Journal of Physiology - Heart and Circulatory Physiology, vol. 312, no. 4, pp. H645-H661.

Systolic blood pressure reduction during the first 24h in acute heart failure admission: Friend or foe?
Cotter, G, Metra, M, Davison, BA, Jondeau, G, Cleland, JGF, Bourge, RC, Milo, O, OConnor, CM, Parker, JD, Torre, G, van Veldhuisen, DJ, Kobrin, I, Rainisio, M, Senger, S, Edwards, C, Mcmurray, JJV & Teerlink, JR 2017, European Journal of Heart Failure.

Live Chat Available